Cabaletta Bio (CABA) Expected to Release Earnings on Monday

Cabaletta Bio (NASDAQ:CABA) is expected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $1.67 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. On average, analysts expect Cabaletta Bio to post ($1.34) EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Cabaletta Bio Stock Performance

Shares of CABA stock opened at $1.51 on Monday. The firm has a fifty day moving average of $2.30 and a 200-day moving average of $2.84. The stock has a market cap of $256.01 million, a price-to-earnings ratio of -0.96 and a beta of 3.56. Cabaletta Bio has a 52-week low of $1.32 and a 52-week high of $4.23.

Analyst Ratings Changes

Several brokerages recently commented on CABA. William Blair raised Cabaletta Bio to a “strong-buy” rating in a research note on Wednesday, September 23rd. Wells Fargo & Company lowered their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen lowered shares of Cabaletta Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Cabaletta Bio in a report on Tuesday, September 1st. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.60.

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.